Regeneron Pharmaceuticals, Inc. (REGN) Q1 2022 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.06%

Regeneron's strong EPS performance indicates better-than-expected profitability, which likely contributed to the slight stock increase. However, the lack of revenue data and guidance may leave investors cautious. The stock's modest reaction suggests that while the EPS beat is positive, investors are looking for more comprehensive insights into future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$11.49	N/A	+22.59%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in the company's current trajectory while acknowledging market challenges. They reiterated their commitment to innovation and growth.

Management highlighted strong performance in key product areas.

They noted ongoing investments in research and development.

There was an emphasis on maintaining a robust pipeline for future growth.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.06%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.06%

Key numbers

Management commentary